Who Paid My Doc
Myfembree
Drug Hormone Therapy
NDC 72974-415-01
General payments
$2,996,721
Research payments
$25,293,681
Through program year 2024, $2,996,721 in general payments and $25,293,681 in research payments were reported against Myfembree (Hormone Therapy).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
8 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $394,671 | 17,952 |
| 2024 | Research | $12,164,980 | 3,155 |
| 2023 | General | $1,006,811 | 29,495 |
| 2023 | Research | $9,194,485 | 2,525 |
| 2022 | General | $1,060,222 | 29,713 |
| 2022 | Research | $2,978,961 | 1,102 |
| 2021 | General | $535,016 | 13,927 |
| 2021 | Research | $955,254 | 280 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2024.
The top 5 of 79 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
The top 5 of 51 states; each share is of general payments naming this product in 2024 where a state was reported.
Records
91,087 general · 7,062 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.